Final results of a phase 1 trial with soquelitinib (SQL), a selective interleukin-2-inducible T cell kinase (ITK) inhibitor for treatment of relapsed/refractory (R/R) T cell lymphomas (TCL)

Richard Miller; Ryan Wilcox; John Reneau; Costas Yannakou; Won Seog Kim; Tatyana Feldman; Youn-H Kim; Michael Khodadoust; Dejan Radeski; Robin Gasiorowski; Dok Hyun Yoon; Yuqin Song; Andrew Hotson; Suresh Mahabhashyam

doi:10.1182/blood-2025-778

Final results of a phase 1 trial with soquelitinib (SQL), a selective interleukin-2-inducible T cell kinase (ITK) inhibitor for treatment of relapsed/refractory (R/R) T cell lymphomas (TCL)

Richard Miller, Ryan Wilcox, John Reneau, Costas Yannakou, Won Seog Kim, Tatyana Feldman, Youn-H Kim, Michael Khodadoust, Dejan Radeski, Robin Gasiorowski, Dok Hyun Yoon, Yuqin Song, Andrew Hotson, Suresh Mahabhashyam

Research output: Contribution to journal › Meeting abstract › peer-review

Original language	English
Pages (from-to)	778-779
Number of pages	2
Journal	Blood
Volume	146
Issue number	Supplement 1
Early online date	2025
DOIs	https://doi.org/10.1182/blood-2025-778
Publication status	Published - 3 Nov 2025
Externally published	Yes
Event	67th Annual Meeting of the American-Society-of-Hematology (ASH) - Orlando Duration: 6 Dec 2025 → 9 Dec 2025

Access to Document

10.1182/blood-2025-778

Cite this

Miller, R., Wilcox, R., Reneau, J., Yannakou, C., Kim, W. S., Feldman, T., Kim, Y.-H., Khodadoust, M., Radeski, D., Gasiorowski, R., Yoon, D. H., Song, Y., Hotson, A., & Mahabhashyam, S. (2025). Final results of a phase 1 trial with soquelitinib (SQL), a selective interleukin-2-inducible T cell kinase (ITK) inhibitor for treatment of relapsed/refractory (R/R) T cell lymphomas (TCL). Blood, 146(Supplement 1), 778-779. https://doi.org/10.1182/blood-2025-778

@article{6d4ee8e9679c44ecb8a65ac24c37ffd6,

title = "Final results of a phase 1 trial with soquelitinib (SQL), a selective interleukin-2-inducible T cell kinase (ITK) inhibitor for treatment of relapsed/refractory (R/R) T cell lymphomas (TCL)",

author = "Richard Miller and Ryan Wilcox and John Reneau and Costas Yannakou and Kim, \{Won Seog\} and Tatyana Feldman and Youn-H Kim and Michael Khodadoust and Dejan Radeski and Robin Gasiorowski and Yoon, \{Dok Hyun\} and Yuqin Song and Andrew Hotson and Suresh Mahabhashyam",

year = "2025",

month = nov,

day = "3",

doi = "10.1182/blood-2025-778",

language = "English",

volume = "146",

pages = "778--779",

journal = "Blood",

issn = "0006-4971",

publisher = "Elsevier",

number = "Supplement 1",

note = "67th Annual Meeting of the American-Society-of-Hematology (ASH) ; Conference date: 06-12-2025 Through 09-12-2025",

}

Miller, R, Wilcox, R, Reneau, J, Yannakou, C, Kim, WS, Feldman, T, Kim, Y-H, Khodadoust, M, Radeski, D, Gasiorowski, R, Yoon, DH, Song, Y, Hotson, A & Mahabhashyam, S 2025, 'Final results of a phase 1 trial with soquelitinib (SQL), a selective interleukin-2-inducible T cell kinase (ITK) inhibitor for treatment of relapsed/refractory (R/R) T cell lymphomas (TCL)', Blood, vol. 146, no. Supplement 1, pp. 778-779. https://doi.org/10.1182/blood-2025-778

Final results of a phase 1 trial with soquelitinib (SQL), a selective interleukin-2-inducible T cell kinase (ITK) inhibitor for treatment of relapsed/refractory (R/R) T cell lymphomas (TCL). / Miller, Richard; Wilcox, Ryan; Reneau, John et al.
In: Blood, Vol. 146, No. Supplement 1, 03.11.2025, p. 778-779.

Research output: Contribution to journal › Meeting abstract › peer-review

TY - JOUR

T1 - Final results of a phase 1 trial with soquelitinib (SQL), a selective interleukin-2-inducible T cell kinase (ITK) inhibitor for treatment of relapsed/refractory (R/R) T cell lymphomas (TCL)

AU - Miller, Richard

AU - Wilcox, Ryan

AU - Reneau, John

AU - Yannakou, Costas

AU - Kim, Won Seog

AU - Feldman, Tatyana

AU - Kim, Youn-H

AU - Khodadoust, Michael

AU - Radeski, Dejan

AU - Gasiorowski, Robin

AU - Yoon, Dok Hyun

AU - Song, Yuqin

AU - Hotson, Andrew

AU - Mahabhashyam, Suresh

PY - 2025/11/3

Y1 - 2025/11/3

U2 - 10.1182/blood-2025-778

DO - 10.1182/blood-2025-778

M3 - Meeting abstract

SN - 0006-4971

VL - 146

SP - 778

EP - 779

JO - Blood

JF - Blood

IS - Supplement 1

T2 - 67th Annual Meeting of the American-Society-of-Hematology (ASH)

Y2 - 6 December 2025 through 9 December 2025

ER -